Xavier Montalban

发表

The progression of brain atrophy is similar in drug-free MS sub-types: A longitudinal study of a large patient population

Marco Rovaris, A Giorgio, Massimo Filippi, 2008 .

Baseline characteristics and patient adherence in the BENEFIT study

Ludwig Kappos, Xavier Montalban, Dh Miller, 2005 .

Abnormal connectivity inside the motor network in patients with multiple sclerosis: a multicentre fMRI study

Paul M. Matthews, Laura Mancini, Massimo Filippi, 2008 .

Validation of the clinical classification scheme using MRI in the BENEFIT Study

T. Korteweg, Xavier Montalban, Gilles Edan, 2005 .

Genetic association between polymorphisms in the ADAMTS14 gene and multiple sclerosis

Arcadi Navarro, Xavier Montalban, Manuel Comabella, 2005, Journal of Neuroimmunology.

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

Bernhard Hemmer, Ludwig Kappos, Stephen L. Hauser, 2017, The New England journal of medicine.

Spinal cord lesions: A modest contributor to diagnosis in clinically isolated syndromes but a relevant prognostic factor

Carlos Nos, Xavier Montalban, Manuel Comabella, 2018, Multiple sclerosis.

The Multiple Sclerosis Care Unit

Gavin Giovannoni, Xavier Montalban, Giancarlo Comi, 2018, Multiple sclerosis.

Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome

Sara Llufriu, Xavier Montalban, Lluís Ramió-Torrentà, 2018, Brain : a journal of neurology.

Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis.

Pablo Villoslada, Xavier Montalban, Antonio Uccelli, 2006, Human molecular genetics.

A genomic screen of Spanish multiple sclerosis patients reveals multiple loci associated with the disease

Pablo Villoslada, Arcadi Navarro, Xavier Montalban, 2003, Journal of Neuroimmunology.

Magnetic resonance imaging predictors of conversion to multiple sclerosis in the BENEFIT study.

Ludwig Kappos, Xavier Montalban, Frederik Barkhof, 2009, Archives of neurology.

Evaluation of the Central Vein Sign as a Diagnostic Imaging Biomarker in Multiple Sclerosis.

Alain Pitiot, Ludwig Kappos, Christian Enzinger, 2019, JAMA neurology.

Long-term safety and efficacy of daclizumab beta in relapsing–remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study

Till Sprenger, Gavin Giovannoni, Eva Kubala Havrdova, 2020, Journal of Neurology.

Heat Shock Protein 70: Roles in Multiple Sclerosis

Xavier Montalban, X. Montalban, C. Espejo, 2012, Molecular medicine.

MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-clinical implementation in the diagnostic process (vol 11, pg 471, 2015)

Ludwig Kappos, Mike P. Wattjes, Massimo Filippi, 2015 .

Genome-wide pharmacogenomic analysis of the response to interferon beta therapy in multiple sclerosis.

Pablo Villoslada, Xavier Montalban, Manuel Comabella, 2008, Archives of neurology.

Genome-wide scan of 500,000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis.

Arcadi Navarro, Xavier Montalban, Manuel Comabella, 2009, Archives of neurology.

Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis

Xavier Montalban, X. Montalban, D. Rotstein, 2019, Nature Reviews Neurology.

Evidence for association of chromosome 10 open reading frame (C10orf27) gene polymorphisms and multiple sclerosis

Carlos Nos, Xavier Montalban, Manuel Comabella, 2008, Multiple sclerosis.

Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial

Ludwig Kappos, Xavier Montalban, David H. Miller, 2016, The Lancet.

A single, early magnetic resonance imaging study in the diagnosis of multiple sclerosis.

Marco Rovaris, Massimo Filippi, Xavier Montalban, 2009, Archives of neurology.

Large-scale, multicentre, quantitative MRI study of brain and cord damage in primary progressive multiple sclerosis

Marco Rovaris, Massimo Filippi, Xavier Montalban, 2008, Multiple sclerosis.

Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis

Alexander Klistorner, Bernhard Hemmer, Pablo Villoslada, 2017, The Lancet Neurology.

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Ludwig Kappos, Margaret Burnett, Gavin Giovannoni, 2018, The Lancet.

MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study

Marco Rovaris, Massimo Filippi, Xavier Montalban, 2007, The Lancet Neurology.

Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders

Bernhard Hemmer, Ludwig Kappos, Maria Assunta Rocca, 2019, The Lancet Neurology.

Semaphorins 3A and 7A: potential immune and neuroregenerative targets in multiple sclerosis.

Xavier Montalban, X. Montalban, H. Eixarch, 2013, Trends in molecular medicine.

Xavier Montalban, Rafael Arroyo, Guillermo Izquierdo, 2014, Neurology: Neuroimmunology & Neuroinflamm.

Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta

Xavier Montalban, James Sheridan, X. Montalban, 2010, The Lancet Neurology.

Ancient and Recent Selective Pressures Shaped Genetic Diversity at AIM2-Like Nucleic Acid Sensors

Xavier Montalban, Sunny Malhotra, Manuel Comabella, 2014, Genome biology and evolution.

Multiple sclerosis: current treatment algorithms.

Xavier Montalban, Manuel Comabella, X. Montalban, 2011, Current opinion in neurology.

Search for Specific Biomarkers of IFNβ Bioactivity in Patients with Multiple Sclerosis

Ramil N. Nurtdinov, Xavier Montalban, Sunny Malhotra, 2011, PloS one.

Relationship between brain MRI lesion load and short-term disease evolution in non-disabling MS: a large-scale, multicentre study

Marco Rovaris, Massimo Filippi, Massimiliano Calabrese, 2011, Multiple sclerosis.

Placebo-controlled trial of oral laquinimod for multiple sclerosis.

Ludwig Kappos, Massimo Filippi, Xavier Montalban, 2012, The New England journal of medicine.

Prognostic relevance of antimyelin antibodies for progression to multiple sclerosis after a first demyelinating event: results from the BENEFIT study

Ludwig Kappos, Xavier Montalban, Frederik Barkhof, 2006 .

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.

Ludwig Kappos, Xavier Montalban, Frederik Barkhof, 2010, The New England journal of medicine.

Assessment of different treatment failure criteria in a cohort of relapsing–remitting multiple sclerosis patients treated with interferon β: Implications for clinical trials

Carlos Nos, Xavier Montalban, Manuel Comabella, 2002, Annals of neurology.

Refining genetic associations in multiple sclerosis

Hanne F. Harbo, Margaret A. Pericak-Vance, Stephen L. Hauser, 2008, The Lancet Neurology.

Clinically isolated syndromes suggestive of multiple sclerosis, part 2: non-conventional MRI, recovery processes, and management

Massimo Filippi, Xavier Montalban, Frederik Barkhof, 2005, The Lancet Neurology.

Brain and cervical spinal cord atrophy in primary progressive multiple sclerosis: results from a placebo-controlled phase III trial (INFORMS)

Ludwig Kappos, Xavier Montalban, Dh Miller, 2015 .

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial

Gavin Giovannoni, Xavier Montalban, Ernst-Wilhelm Radue, 2013, The Lancet.

Oral fingolimod (FTY720) for relapsing multiple sclerosis.

Ludwig Kappos, Xavier Montalban, Giancarlo Comi, 2006, The New England journal of medicine.

Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study

Bernhard Hemmer, Ludwig Kappos, Xavier Montalban, 2013, The Lancet Neurology.

Quantifying brain tissue volume in multiple sclerosis with automated lesion segmentation and filling

Xavier Lladó, Arnau Oliver, Xavier Montalban, 2015, NeuroImage: Clinical.

Treatment decisions in multiple sclerosis — insights from real-world observational studies

Xavier Montalban, Maria Pia Sormani, Jan Hillert, 2017, Nature Reviews Neurology.

Overcoming Therapeutic Inertia in Multiple Sclerosis Care: A Pilot Randomized Trial Applying the Traffic Light System in Medical Education

Xavier Montalban, Philippe N. Tobler, Gustavo Saposnik, 2017, Front. Neurol..